Prosecution Insights
Last updated: August 06, 2026

Spinalcyte LLC

9 pending office actions • 3 art units • 7 examiners • 0 of 9 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
5
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

7
Hard (78%)
1
Medium (11%)
1
Easy (11%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (11%)
§112 only1 (11%)
Multi-statute (no §101)7 (78%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
89% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
11% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MIANO, JOSEPH PAUL 2 36.1% +64.0%
PYLA, EVELYN Y 2 55.8% +47.5%
JOHNSON, KARA D 1 69.3% +24.4%
SCHUBERG, LAURA J 1 23.7% +37.2%
FOX, ALLISON M 1 71.4% +35.3%
SINGH, ANOOP KUMAR 1 42.7% +67.3%
CORDAS, EMILY ANN 1 50.4% +58.1%

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
17453143 FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE PYLA, EVELYN Y 52d overdue
17052841 DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION MIANO, JOSEPH PAUL 36d overdue
17755837 FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE FOX, ALLISON M 20d
18905224 TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF JOHNSON, KARA D
17996392 TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF SCHUBERG, LAURA J
17052845 INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE SINGH, ANOOP KUMAR
16068096 CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS CORDAS, EMILY ANN

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17453143 FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE PYLA, EVELYN Y 52d overdue
17052841 DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION MIANO, JOSEPH PAUL 36d overdue
17755837 FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE FOX, ALLISON M 20d
18905224 TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF JOHNSON, KARA D
18345022 DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION MIANO, JOSEPH PAUL
17996392 TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF SCHUBERG, LAURA J
17052845 INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE SINGH, ANOOP KUMAR
16068096 CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS CORDAS, EMILY ANN

Top Art Units

Art UnitApps
1631 3
1633 3
1632 2

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18905224 TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF JOHNSON, KARA D §103§112 Non-Final OA Pending Oct 03, 2024
18345022 DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION MIANO, JOSEPH PAUL 1631 §103Other Non-Final OA Pending Jun 30, 2023
17996392 TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF SCHUBERG, LAURA J 1631 §102§103 Final Rejection Pending Oct 17, 2022
17755837 FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE FOX, ALLISON M 1633 §103§112Other Non-Final OA 20d Pending May 10, 2022
17453143 FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE PYLA, EVELYN Y 1633 §103§112 Non-Final OA 52d overdue Pending Nov 01, 2021
17052845 INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE SINGH, ANOOP KUMAR 1632 §103§112 Non-Final OA Pending Nov 04, 2020
17052841 DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION MIANO, JOSEPH PAUL 1631 §103§112Other Final Rejection 36d overdue Pending Nov 04, 2020
16068096 CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS CORDAS, EMILY ANN 1632 §103§112 Final Rejection Pending Dec 17, 2018
14357558 FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE PYLA, EVELYN Y 1633 §112 Final Rejection Pending May 09, 2014

Managing Spinalcyte LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month